MRUS

Merus NV

Add to Watchlist

Advanced Chart

64.000

+0.61(0.962%)1D

Overview
Forecast
Valuation
Earnings

Line

Candle

YTD

High

64.000

Open

63.800

VWAP

63.27

Vol

557.23K

Mkt Cap

4.84B

Low

63.000

Amount

35.26M

EV/EBITDA(TTM)

Total Shares

67.37M

4.08B

EV/OCF(TTM)

P/S(TTM)

78.07

Merus NV is the Netherlands - based biotechnology company, concentrated on developing differentiating therapeutics for cancer patients. The product programs in the Merus pipeline are based on the Multiclonics format. Its products are designed to bind to multiple targets, and are manufactured with features for anti-cancer effects against the complex mechanisms that drive cancer. Company's products engage cancer antigens and harness the power of the immune system to kill tumor cells by utilizing technology platform. One of the drug zenocutuzumab (Zeno), a Biclonics antibody, concentrates on helping patients with lung, pancreatic and other types of solid tumors. The company operates in the Netherlands and United States.

Market Estimates

Earnings Estimates

Revenue

YoY Chg

EPS

YoYChg

FY2026Q1

FY2025Q4

FY2025Q3

5.97M

-77.47%

-1.290

-7.86%

9.12M

-0.21%

-1.127

+130.02%

9.07M

-22.95%

-1.133

-22.43%

Estimates Revision

The market is revising Upward the revenue expectations for Merus N.V. (MRUS) for FY2025, with the revenue forecasts being adjusted by 36.29% over the past three months. During the same period, the stock price has changed by 49.64%.

Revenue Estimates for FY2025

Revise Upward

+36.29%

In Past 3 Month

EPS Estimates for FY2025

Revise Upward

+7.83%

In Past 3 Month

Stock Price

Go Up

+49.64%

In Past 3 Month

13 Analyst Rating

47.97% Upside

Wall Street analysts forecast MRUS stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MRUS is 94.70 USD with a low forecast of 67.00 USD and a high forecast of 110.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

13 Buy

0 Hold

0 Sell

Strong Buy

47.97% Upside

Current: 64.000

Low

67.00

Averages

94.70

High

110.00

47.97% Upside

Current: 64.000

Low

67.00

Averages

94.70

High

110.00

BofA

Buy

upgrade

$70 -> $92

2025-05-23

Reason

BofA

Price Target

$70 -> $92

2025-05-23

upgrade

Buy

Reason

BofA raised the firm's price target on Merus to $92 from $70 and keeps a Buy rating on the shares after the company reported 12-month landmark objective survival of 79% in its full phase 2 cohort for petosemtamab plus pembrolizumab. This OS rate compares favorably to the historical 50%-59% benchmark for pembro monotherapy in first-line head and neck squamous cell carcinoma and is also significantly higher than the 50%-60% range the firm's doctor checks had indicated would be "good data," the analyst tells investors. The firm thinks the data sets the "peto'+pembro" combination up to be "the best-in-class treatment option for this patient population," the analyst added.

BMO Capital

Etzer Darout

Outperform

upgrade

$96 -> $110

2025-05-23

Reason

BMO Capital

Etzer Darout

Price Target

$96 -> $110

2025-05-23

upgrade

Outperform

Reason

BMO Capital analyst Etzer Darout raised the firm's price target on Merus to $110 from $96 and keeps an Outperform rating on the shares. The firm notes that ASCO readouts are off to a strong start with the updated Phase 2 data of Merus's petosemtamab + pembro in first-line HNSCC, the analyst tells investors in a research note. BMO adds that it has a higher confidence in the approvability of petosemtamab in HNSCC, with probability of success rising to 90% from 85%.

Wells Fargo

Overweight

downgrade

$91 -> $89

2025-05-08

Reason

Wells Fargo

Price Target

$91 -> $89

2025-05-08

downgrade

Overweight

Reason

Wells Fargo lowered the firm's price target on Merus to $89 from $91 and keeps an Overweight rating on the shares. The firm says there was not much new on the PR as the company continues to execute on its petosemtamab studies. Wells sees the ASCO update in first-line HNSCC and the mCRC update in the second half of 2025 for petosemtamab as the key catalysts in the next 12 months.

Needham

Ami Fadia

Strong Buy

Reiterates

$83

2025-04-09

Reason

Needham

Ami Fadia

Price Target

$83

2025-04-09

Reiterates

Strong Buy

Reason

Guggenheim

Michael Schmidt

Strong Buy

Reiterates

$109

2025-03-28

Reason

Guggenheim

Michael Schmidt

Price Target

$109

2025-03-28

Reiterates

Strong Buy

Reason

Guggenheim

Michael Schmidt

Strong Buy

Reiterates

$109

2025-03-18

Reason

Guggenheim

Michael Schmidt

Price Target

$109

2025-03-18

Reiterates

Strong Buy

Reason

See All Ratings

Valuation Metrics

The current forward P/E ratio for Merus NV (MRUS.O) is -13.48, compared to its 5-year average forward P/E of -9.97. For a more detailed relative valuation and DCF analysis to assess Merus NV 's fair value, click here.

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.

N/A

5Y Average PE

-9.97

Current PE

-13.48

Overvalued PE

-6.57

Undervalued PE

-13.38

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.

N/A

5Y Average EV/EBITDA

-6.03

Current EV/EBITDA

-10.72

Overvalued EV/EBITDA

-2.66

Undervalued EV/EBITDA

-9.40

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.

Strongly Overvalued

5Y Average PS

40.45

Current PS

165.30

Overvalued PS

70.43

Undervalued PS

10.46